Liatermin

Drug Profile

Liatermin

Alternative Names: BVF-014; GDNF; Glial-derived neutrotrophic factor; r-metHuGDNF

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; MedGenesis Therapeutix
  • Class Antiparkinsonians; Biological proteins; Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy; Parkinson's disease; Sensorineural hearing loss
  • Discontinued Amyotrophic lateral sclerosis; Deafness; Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Epilepsy in Canada (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Canada (Intracerebral, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Sensorineural hearing loss in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top